

Contacts:

IPM Africa: Leonard Solai, lsolai@IPMglobal.org, +27.84 6606 776
IPM US/Europe: Holly Seltzer, hseltzer@IPMglobal.org, +1.301.608.4277

IPM's Dapivirine Ring for Women's HIV Prevention Receives WHO Prequalification

- *WHO prequalification brings the dapivirine vaginal ring another step closer to introduction, pending country approvals*
- *Confirms that this new HIV prevention method meets global standards for quality, safety and efficacy*

SILVER SPRING, Md. (November 30, 2015) —

This designation from the WHO confirms that the ring meets the standards of the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) under

[Article 58.](#)

"WHO prequalification brings the dapivirine ring an important step closer to being made available to women, who want and deserve to have effective HIV prevention options. In sub-Saharan Africa, women are at a persistently high HIV risk."

The [WHO prequalification](#)

_____ program facilitates access to quality-assured medicines that respond to urgent public health priorities. Many countries consider prequalification in their regulatory reviews.

Women bear a disproportionate burden of the global HIV/AIDS epidemic, with nearly 60% of new adult infections in sub-Saharan Africa occurring

